Achieve Life Sciences, Inc. (ACHV) News

Achieve Life Sciences, Inc. (ACHV): $7.28

0.14 (+1.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACHV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

Filter ACHV News Items

ACHV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACHV News Highlights

  • For ACHV, its 30 day story count is now at 3.
  • Over the past 2 days, the trend for ACHV's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • WASH are the most mentioned tickers in articles about ACHV.

Latest ACHV News From Around the Web

Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows: H.C. Wainwright BIOCONNECT Virtual Conference: Date: January 10, 2022 Time: 7:00 am ET Investors can register for the conference HERE . Following the conference, a webcast replay of the presentation will be available on Full story available on Benzinga.com

Benzinga | January 6, 2022

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Topline ORCA-2 Results Expected in Q2 2022SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021. The ORCA-2 trial is the first

Yahoo | January 4, 2022

Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development

SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. ("SVB"). The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness to Achieve at closing on December 22, 2021. Subject to the terms and conditions of the ...

Benzinga | December 22, 2021

Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program

Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. Related: Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation. As part of the contingent convertible debt agreement, SVB will fund $15 million in the fo

Yahoo | December 22, 2021

Geode Capital Management LLC Purchases 27,379 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Geode Capital Management LLC grew its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 93.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,669 shares of the biopharmaceutical companys stock after acquiring an additional 27,379 shares []

Transcript Daily | November 27, 2021

Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual panel event on smoking and e-cigarette cessation on Thursday, December 2nd, 2021, at 1:00 PM EST.

Intrado Digital Media | November 23, 2021

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct

Intrado Digital Media | November 22, 2021

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 11, 2021

ACHV: Early 2022 Start to ORCA-3 and ORCA-V1

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Third Quarter 2021 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter results in a press release and held a conference call after market close on November 9, 2021. The company concurrently filed its Form 10-Q with the SEC. Highlights for the third quarter ended September 30th and to-date include: ➢ NIH

Yahoo | November 11, 2021

Achieve Life Sciences (NASDAQ:ACHV) Announces Earnings Results, Beats Estimates By $0.38 EPS

Achieve Life Sciences (NASDAQ:ACHV) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks consensus estimate of ($1.09) by $0.38, MarketWatch Earnings reports. During the same quarter in the prior year, the company earned ($1.14) earnings per share. Shares of NASDAQ ACHV traded []

Dakota Financial News | November 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.924 seconds.